Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 8Active not recruiting 4Terminated 2Not yet recruiting 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 159Neoplasms 116Carcinoma, Non-Small-Cell Lung 91Colorectal Neoplasms 86Prostatic Neoplasms 85Lung Neoplasms 78Leukemia, Myeloid, Acute 54Carcinoma, Hepatocellular 52Pancreatic Neoplasms 46Neoplasm Metastasis 44Multiple Myeloma 38Recurrence 35Triple Negative Breast Neoplasms 31Squamous Cell Carcinoma of Head and Neck 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Ovarian Neoplasms 29Melanoma 28Uterine Cervical Neoplasms 27Stomach Neoplasms 27Glioblastoma 27Brain Neoplasms 27Rectal Neoplasms 25Head and Neck Neoplasms 25Small Cell Lung Carcinoma 23Carcinoma, Renal Cell 23Endometrial Neoplasms 20Lymphoma, B-Cell 19Glioma 19Sarcoma 18Lymphoma, Follicular 18

Interventions

Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Epstein-Barr Virus Infections × 90 days × Clear all
NCT07614282 2026-05-29

Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia

Columbia University

Phase 1 Not yet recruiting
28 enrolled

Infections, Epstein-Barr Virus Infections

NCT07557602 2026-04-29

mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults

Vaccine Company, Inc.

Phase 1 Not yet recruiting
45 enrolled

Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡